Nat Rev Rheumatol
-
Publication Venue For
- Hypothetical model ignores many important pathophysiologic mechanisms in fibromyalgia.. 19:321. 2023
- A comprehensive guide for managing the reproductive health of patients with vasculitis.. 18:711-723. 2022
- Author Correction: Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021.. 18:734. 2022
- Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021.. 18:465-479. 2022
- Are DNA-HLA class II interactions the missing link in SLE?. 17:647-648. 2021
- Reply to: Diagnostic role of anti-dsDNA antibodies: do not forget autoimmune hepatitis.. 17:245. 2021
- Cross-trial comparisons in reviews: proceed with caution.. 16:663-664. 2020
- Safety and efficacy of HSCT for systemic sclerosis across clinical trials.. 16:661. 2020
- New insights into the role of antinuclear antibodies in systemic lupus erythematosus.. 16:565-579. 2020
- Core and adjunctive interventions for osteoarthritis: efficacy and models for implementation.. 16:434-447. 2020
- Allogeneic HSCT for autoimmune disease: a shared decision.. 15:701-702. 2019
- Establishing outcome measures in early knee osteoarthritis.. 15:438-448. 2019
- If patients are the true north, patient-centeredness should guide research.. 15:5-6. 2019
- Using social media to promote medication adherence.. 14:445-446. 2018
- Biomarkers as drug development tools: discovery, validation, qualification and use.. 14:354-362. 2018
- Update on outcome assessment in myositis.. 14:303-318. 2018
- Antinuclear antibody testing - misunderstood or misbegotten?. 13:495-502. 2017
- Fine tuning of immunometabolism for the treatment of rheumatic diseases.. 13:313-320. 2017
- Anti-DNA antibodies--quintessential biomarkers of SLE.. 12:102-110. 2016
- Does lipopolysaccharide-mediated inflammation have a role in OA?. 12:123-129. 2016
- The role of hedgehog signalling in skeletal health and disease.. 11:552-560. 2015
- The eye: a window of opportunity in rheumatoid arthritis?. 10:552-560. 2014
- Autoimmunity: regulatory B cells--IL-35 and IL-21 regulate the regulators.. 10:452-453. 2014
- Progress in intra-articular therapy.. 10:11-22. 2014
- The phenotypic and genetic signatures of common musculoskeletal pain conditions.. 9:340-350. 2013
- Paediatric rheumatic disease: lessons from SLE: children are not little adults.. 8:444-445. 2012
- HMGB1: a multifunctional alarmin driving autoimmune and inflammatory disease.. 8:195-202. 2012
- Challenges in the diagnosis and treatment of juvenile systemic sclerosis.. 7:676-680. 2011
- Clinical features, pathogenesis and treatment of juvenile and adult dermatomyositis.. 7:664-675. 2011
- Are autoantibodies the targets of B-cell-directed therapy?. 7:551-556. 2011
- Microparticles as autoadjuvants in the pathogenesis of SLE.. 6:368-372. 2010
- Psychological approaches to understanding and treating arthritis pain.. 6:210-216. 2010
- The role of microparticles in the pathogenesis of rheumatic diseases.. 6:21-29. 2010
- CD19: a promising B cell target for rheumatoid arthritis.. 5:572-577. 2009